- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06643780
RANK-ligandin esto sarkopenian ja taustalla olevan osteoporoosin torjumiseksi
RANK-ligandin esto sarkopeniaa ja taustalla olevaa osteoporoosia vastaan: satunnaistettu, kaksoissokkoutettu, kaksoisnukke, aktiivisesti kontrolloitu koe
The objective of this study was to conduct a randomized, double-blind, double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Aims:
- To assess whether receptor activator of nuclear factor-kB ligand (RANKL)-inhibition can treat sarcopenia in osteosarcopenic patients, in terms of appendicular skeletal muscle mass (ASM), handgrip strength, and physical performance.
- To assess whether RANKL-inhibition improves quality of life, and decreases falls, fractures, hospital admissions and mortality in osteosarcopenic patients.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Ronald Man Yeung Wong
- Puhelinnumero: 852 3505 1654
- Sähköposti: ronald.wong@cuhk.edu.hk
Opiskelupaikat
-
-
-
Hong Kong, Kiina
- Rekrytointi
- The Chinese University of Hong Kong
-
Ottaa yhteyttä:
- Ronald Man Yeung Wong
- Puhelinnumero: 852 3505 1654
- Sähköposti: ronald.wong@cuhk.edu.hk
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Elderly males or females aged 65 years or older
- diagnosed with osteosarcopenia (sarcopenia diagnosis based on AWGS 2019 guidelines - low appendicular skeletal muscle mass (ASM) by Dual-energy X-ray absorptiometry (DXA) (M:<7.0kg/m2, F:<5.4kg/m2) AND low handgrip strength (M:<28kg, F:<18kg) OR low physical performance (6-metre walk: <1.0m/s or 5-time chair stand test ≥ 12 s); osteoporosis diagnosed based on World Health Organization (WHO) criteria with DXA scan T-score ≤ -2.5)
- Willing and able to comply with study protocol including follow-up evaluations.
Exclusion Criteria:
- history of recent fracture i.e., within 3 months
- history of prior anti-osteoporotic drug
- disease or medication affecting bone or muscle metabolism
- Chairbound or bedbound
- Unable to agree for consent
- contraindication to drug i.e., Denosumab or Zoledronic Acid
- Underlying malignancy or disease known to cause cachexia
- severe renal impairment e.g., Creatinine Clearance (CrCl) < 35ml/min
- moderate to severe liver failure (Child-Pugh Class B or C).
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kolminkertaistaa
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Denosumab group
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly |
|
Placebo Comparator: Zolendronic acid group
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
6-metre walk
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The time taken to walk 6 metres without deceleration. Average result of 2 trials is recorded. Slow speed is defined as &lt;1.0m/s. |
From enrollment to the end of treatment at 52 weeks
|
|
5-time chair stand test
Aikaikkuna: From enrollment to the end of treatment at 8 weeks
|
The time to rise from a chair 5 times is recorded. The cut-off for is taken at &gt;=12 seconds. |
From enrollment to the end of treatment at 8 weeks
|
|
Appendicular skeletal muscle mass (ASM)
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Determined with Dual-energy X-ray absorptiometry (Horizon®, DXA system, Hologic, USA). Total ASM by DXA is evaluated by segmented measurement of muscle mass at four limbs by operator-defined cutlines at specific anatomical landmarks. ASM is adjusted to square of height to calculate ASMI (kg/m2). Low ASMI by DXA is &lt; 7 kg/m2 for men and 5.4 kg/m2 for women. |
From enrollment to the end of treatment at 52 weeks
|
|
Handgrip strength
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Assessed by spring-type hand dynamometer (JAMAR Hand Dynamometer 5030JO). Cut-off for men is &lt; 28kg, and female is &lt;18kg. Maximum reading of 3 trials using dominant hand in a maximum-effort isometric contraction |
From enrollment to the end of treatment at 52 weeks
|
|
Quadriceps muscle strength
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Measured on affected limb with isometric dynamometer (Baseline, Genova, Italy). Subject will sit on a chair with both feet above ground, while raising the affected leg 45° forwards. The dynamometer is placed above the ankle and the subject will push the leg forward with maximum force. Measurements will be repeated 3 times and maximum value will be used for evaluation |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes directional control (%). |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes movement velocity (degrees/s) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes endpoint excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes maximum excursion (%) |
From enrollment to the end of treatment at 52 weeks
|
|
Balancing ability
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The Basic Balance Master System (NeuroCom International Inc, USA) is used to measure static and dynamic ability of subjects to maintain center of balance. Subjects will stand barefoot on force plate and control location of their center-of-gravity by weight-shifting to eight different targets. Measured parameters of limits of stability test includes reaction time(s) |
From enrollment to the end of treatment at 52 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Falls
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
To assess the occurrence of falls, patients are required to self-report via a fall calendar, which will be returned at 1-year |
From enrollment to the end of treatment at 52 weeks
|
|
Fracture
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Assess occurrence of a fracture within a year of study period. |
From enrollment to the end of treatment at 52 weeks
|
|
Quality of life Short Form-36 (SF-36)
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
The highest score is 900, and the lowest score is 0. Highest score indicates a better quality of life. |
From enrollment to the end of treatment at 52 weeks
|
|
Physical activity scale for elderly (PASE)
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
It assesses the types of activities typically chosen by older adults, ranging from 0 to 793, with higher scores indicating greater physical activity |
From enrollment to the end of treatment at 52 weeks
|
|
Food frequency questionnaire
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Daily and weekly intake of 280 food items will be performed using a validated food frequency questionnaire developed in a local population survey. Mean nutrient quantitation and energy intake per day will be calculated referring to food composition tables derived from the Chinese Medical Sciences Institute and Centre for Food Safety in Hong Kong. |
From enrollment to the end of treatment at 52 weeks
|
|
Hospital admissions
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Number and cause of emergency hospital admission within 1 year of study period are documented. |
From enrollment to the end of treatment at 52 weeks
|
|
Mortality
Aikaikkuna: From enrollment to the end of treatment at 52 weeks
|
Mortality within 1-year of study period is documented. |
From enrollment to the end of treatment at 52 weeks
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 2022.555
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .